However, the removal of IL-12, IL-15, IL-21, IL-23, and IL-33 (see Appendix B Figure A4) from the plasma of patients with MS was more pronounced and, for IL-12 and IL-15, statistically significant (Figure 2). Here, IL33 is linked to myeloid sarcoma.